Blog

Drive-through diagnostic testing?

A story in the UK press on 21 November 2017, Cancer tests in supermarket car parks in bid to boost detection rates, elicited the comment from Diaceutics of “Now that’s progress!” Our vision is that better testing leads to better patient outcomes and earlier diagnosis in the patient journey is a big part of that. […]

Can we improve the pre-analytical steps of laboratory diagnostic testing?

Precision or personalized medicine is taking us into an era of unprecedented breakthroughs in patient treatment and its progress depends to a great extent upon the best possible diagnostic testing. Optimizing test implementation at the laboratory level can be achieved efficiently and these improvements can directly impact and shape testing and patient outcomes. Real-time testing […]

Can laboratories’ experience of PD-L1 companion diagnostic testing be improved? 

During the last few years there has been intense debate about the biomarker PD-L1. It has become a significant feature of precision medicine but its uptake in diagnostic testing has been affected by a number of factors such as availability in labs, confusion over testing options, the platforms required and the interpretation and reporting of results. It’s a situation Diaceutics […]

Getting a great view of the companion diagnostic landscape  

With another FDA approval for Merck’s Keytruda, this time for gastric cancer, we see the onward march of PD-L1 therapy development. This time the therapy has been approved alongside the Agilent Technology companion diagnostic 22C3 pharmDx kit to test for PD-L1 IHC. When a therapy is approved for a new indication, pharma companies can benefit from an in-depth landscape analysis of a particular companion diagnostic market in order to understand the testing options for an advanced disease, the sample availability, the […]